FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2570295101> ?p ?o ?g. }

• W2570295101 abstract "Abstract Abstract 3567 Leukemia is the most common cancer among children under the age of 15 years in the United States and many developed countries. In recent years, there has been the emergence of novel therapeutic drugs for this disease. However, the development of drug resistance by the tumor cells remains the most important obstacle in the treatment of leukemia. A widely studied mechanism of tumor resistance to chemotherapeutic drugs is through the expression of the multi-drug resistance (MDR) genes. P-glycoprotein 170 (gp-170) is an MDR1 gene product which serves as an ATP-dependent cell membrane transporter; it facilitates the efflux of xenobiotics (including chemotherapeutic drugs) from the cells to prevent damage for prolonged drug activity, including chemotherapeutics agents. In addition to MDR1, several reports in different cancers have indicated that the transcription factor Yin Yang 1 (YY1) is over-expressed and regulates tumor cell response to chemotherapeutic drugs. Thus, we hypothesized that YY1 may also be over-expressed in ALL and that its expression may be correlated with the expression of gp-170. We also hypothesized that the co-expression of YY1 and gp-170 may be of prognostic significance in high risk ALL patients. These hypotheses were examined with childhood ALL (n= 88) (of median age 8.2 years, range 0.21–16). The expression of YY1 and gp-170 was determined by IHC in tumor tissues and the frequency of YY1 positive cells was determined. For comparison, normal controls were also analyzed (n= 53). The findings demonstrate that were a significant increase in the frequency of positive cells in ALL compared to controls for both YY1 (38% vs. 8%, p= 0.0001) and for gp-170 (42% vs. 12%, p= 0.001). There was a good correlation between the expression of YY1 and gp-170 using Pearson's test, r=0.4, p=0.0001. We then examined if the co-expression of YY1 and gp-170 is also associated with decreased risk. Indeed, patients with low risk (L1) had significantly less frequency of positive cells compared to patients with high risk for both YY1 (40% vs. 30%, p=0.045) and for gp-170 (48% vs. 35%, p=0.0003). The strong correlation betweenYY1 and gp-170 expression suggested that there may be a cross-talk. TESS analysis demonstrated that the gp-170 proximal promoter contains four putative binding sites for the YY-1 protein. The gp-170 protein was cloned and we developed a luciferase reporter assay. Examination of the putative YY1 binding sites that were individually mutated revealed that mutation at the sites -1860 and -270 abolished activity. Mutation at the site -1420 abolished approximately 50% and mutation at -1230 abolished approximately 75%. Further, CHIP analysis demonstrated that YY1 binds directly to the gp-170 gene. Transfection of cells with YY1 siRNA inhibited the efflux of adriamycin from the cells confirming the regulation of gp-170 expression by YY1. Overall, the findings above demonstrate that both gp-170 and YY1 are over-expressed in childhood ALL and further over-expressed in patients with high risk. The findings suggest that YY1 may be a therapeutic target in MDR positive ALL and its inhibition may reverse resistance to chemotherapeutic drugs. Disclosures: No relevant conflicts of interest to declare." @default.
• W2570295101 created "2017-01-13" @default.
• W2570295101 creator A5003564189 @default.
• W2570295101 creator A5006349708 @default.
• W2570295101 creator A5020496634 @default.
• W2570295101 creator A5027111227 @default.
• W2570295101 creator A5032936893 @default.
• W2570295101 creator A5054264856 @default.
• W2570295101 creator A5055490703 @default.
• W2570295101 creator A5061310711 @default.
• W2570295101 creator A5066323906 @default.
• W2570295101 creator A5067305483 @default.
• W2570295101 creator A5074696019 @default.
• W2570295101 creator A5082889084 @default.
• W2570295101 date "2011-11-18" @default.
• W2570295101 modified "2023-10-18" @default.
• W2570295101 title "Co-Overexpression of YY1 and Gp-170 (MDR1) in Childhood Acute Lymphocytic Leukemia (ALL): Transcription Regulation of Gp-170 by YY1 and Prognostic Significance," @default.
• W2570295101 doi "https://doi.org/10.1182/blood.v118.21.3567.3567" @default.
• W2570295101 hasPublicationYear "2011" @default.
• W2570295101 type Work @default.
• W2570295101 sameAs 2570295101 @default.
• W2570295101 citedByCount "1" @default.
• W2570295101 crossrefType "journal-article" @default.
• W2570295101 hasAuthorship W2570295101A5003564189 @default.
• W2570295101 hasAuthorship W2570295101A5006349708 @default.
• W2570295101 hasAuthorship W2570295101A5020496634 @default.
• W2570295101 hasAuthorship W2570295101A5027111227 @default.
• W2570295101 hasAuthorship W2570295101A5032936893 @default.
• W2570295101 hasAuthorship W2570295101A5054264856 @default.
• W2570295101 hasAuthorship W2570295101A5055490703 @default.
• W2570295101 hasAuthorship W2570295101A5061310711 @default.
• W2570295101 hasAuthorship W2570295101A5066323906 @default.
• W2570295101 hasAuthorship W2570295101A5067305483 @default.
• W2570295101 hasAuthorship W2570295101A5074696019 @default.
• W2570295101 hasAuthorship W2570295101A5082889084 @default.
• W2570295101 hasConcept C101762097 @default.
• W2570295101 hasConcept C104317684 @default.
• W2570295101 hasConcept C114851261 @default.
• W2570295101 hasConcept C133936738 @default.
• W2570295101 hasConcept C150194340 @default.
• W2570295101 hasConcept C159654299 @default.
• W2570295101 hasConcept C203014093 @default.
• W2570295101 hasConcept C2777938653 @default.
• W2570295101 hasConcept C2778384904 @default.
• W2570295101 hasConcept C2778461978 @default.
• W2570295101 hasConcept C2778707650 @default.
• W2570295101 hasConcept C502942594 @default.
• W2570295101 hasConcept C542903549 @default.
• W2570295101 hasConcept C54355233 @default.
• W2570295101 hasConcept C62944979 @default.
• W2570295101 hasConcept C71924100 @default.
• W2570295101 hasConcept C86339819 @default.
• W2570295101 hasConcept C86803240 @default.
• W2570295101 hasConceptScore W2570295101C101762097 @default.
• W2570295101 hasConceptScore W2570295101C104317684 @default.
• W2570295101 hasConceptScore W2570295101C114851261 @default.
• W2570295101 hasConceptScore W2570295101C133936738 @default.
• W2570295101 hasConceptScore W2570295101C150194340 @default.
• W2570295101 hasConceptScore W2570295101C159654299 @default.
• W2570295101 hasConceptScore W2570295101C203014093 @default.
• W2570295101 hasConceptScore W2570295101C2777938653 @default.
• W2570295101 hasConceptScore W2570295101C2778384904 @default.
• W2570295101 hasConceptScore W2570295101C2778461978 @default.
• W2570295101 hasConceptScore W2570295101C2778707650 @default.
• W2570295101 hasConceptScore W2570295101C502942594 @default.
• W2570295101 hasConceptScore W2570295101C542903549 @default.
• W2570295101 hasConceptScore W2570295101C54355233 @default.
• W2570295101 hasConceptScore W2570295101C62944979 @default.
• W2570295101 hasConceptScore W2570295101C71924100 @default.
• W2570295101 hasConceptScore W2570295101C86339819 @default.
• W2570295101 hasConceptScore W2570295101C86803240 @default.
• W2570295101 hasLocation W25702951011 @default.
• W2570295101 hasOpenAccess W2570295101 @default.
• W2570295101 hasPrimaryLocation W25702951011 @default.
• W2570295101 hasRelatedWork W146005878 @default.
• W2570295101 hasRelatedWork W1534849404 @default.
• W2570295101 hasRelatedWork W1584779645 @default.
• W2570295101 hasRelatedWork W1978493021 @default.
• W2570295101 hasRelatedWork W2020644683 @default.
• W2570295101 hasRelatedWork W2022039464 @default.
• W2570295101 hasRelatedWork W2064349177 @default.
• W2570295101 hasRelatedWork W2131515122 @default.
• W2570295101 hasRelatedWork W2171218640 @default.
• W2570295101 hasRelatedWork W2277772680 @default.
• W2570295101 hasRelatedWork W2286862949 @default.
• W2570295101 hasRelatedWork W2316056447 @default.
• W2570295101 hasRelatedWork W2406997352 @default.
• W2570295101 hasRelatedWork W2418085241 @default.
• W2570295101 hasRelatedWork W2467718828 @default.
• W2570295101 hasRelatedWork W2479981302 @default.
• W2570295101 hasRelatedWork W2781601055 @default.
• W2570295101 hasRelatedWork W2953759164 @default.
• W2570295101 hasRelatedWork W2978102388 @default.
• W2570295101 hasRelatedWork W1564083762 @default.
• W2570295101 isParatext "false" @default.
• W2570295101 isRetracted "false" @default.
• W2570295101 magId "2570295101" @default.
• W2570295101 workType "article" @default.